BridgeBio Pharma Files 8-K on Financials and Operations

Ticker: BBIO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1743881

Bridgebio Pharma, Inc. 8-K Filing Summary
FieldDetail
CompanyBridgebio Pharma, Inc. (BBIO)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.001, $500 million
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, operations, sec-filing

TL;DR

BridgeBio Pharma dropped an 8-K detailing financials and operations. Check it out.

AI Summary

BridgeBio Pharma, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also included disclosures related to Regulation FD and other events, along with financial statements and exhibits. The company is incorporated in Delaware and headquartered in Palo Alto, California.

Why It Matters

This 8-K filing provides investors with crucial updates on BridgeBio Pharma's financial health and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial and operational information, not indicating any immediate or significant new risks.

Key Players & Entities

  • BridgeBio Pharma, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of Incorporation
  • Palo Alto, CA (location) — Principal Executive Offices
  • January 13, 2025 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing for BridgeBio Pharma, Inc.?

The primary purpose is to report on the company's results of operations and financial condition, as well as to provide Regulation FD disclosures and other events.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on January 13, 2025.

Where are BridgeBio Pharma, Inc.'s principal executive offices located?

BridgeBio Pharma, Inc.'s principal executive offices are located at 3160 Porter Dr., Suite 250, Palo Alto, CA 94304.

In which state is BridgeBio Pharma, Inc. incorporated?

BridgeBio Pharma, Inc. is incorporated in Delaware.

What is the SIC code for BridgeBio Pharma, Inc.?

The Standard Industrial Classification (SIC) code for BridgeBio Pharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,385 words · 6 min read · ~5 pages · Grade level 13.3 · Accepted 2025-01-13 16:53:07

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
  • $500 million — elease states that the Company received $500 million upon acoramidis U.S. Food and Drug Admi

Filing Documents

01

Item 7.01 Regulation FD Disclosure. The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01, and a copy of the press release referenced in Item 2.02 is furnished as Exhibit 99.1 hereto. The information contained in Items 2.02 and 7.01, as well as Exhibit 99.1, to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01

Item 8.01 Other Events. On January 13, 2025, the Company also presented a business update at the 43 rd Annual J.P. Morgan Healthcare Conference. A copy of the Company's presentation slides, which has been published on the Company's website, is filed as Exhibit 99.2 to this current report on Form 8-K and is incorporated by reference herein.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements. Statements in this Current Report on Form 8-K or the materials furnished or filed herewith may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as "anticipates," "believes," "continues," "estimates," "expects," "hopes," "intends," "may," "plans," "projects," "remains," "seeks," "should," "will," and variations of such words or similar expressions. The Company intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including express and implied statements relating to the Company's expectations regarding the commercial success of Attruby; the Company's clinical trials, including the timing of the last patient-last visit and topline data readouts for each of FORTIFY, CALIBRATE, and PROPEL 3; the potential for encaleret to become a new treatment for ADH1; the potential for BBP-418 to become a new treatment for LGMD2I/R9; the potential for infigratinib to become a new treatment for achondroplasia; timing of approval of Attruby for ATTR-CM in the European Union and Japan; and the Company's preliminary and unaudited estimate of cash and the Company's anticipated funding of its current operations and related timelines; and the Company's expectations regarding reaching regulatory milestones and receipt of milestone payments, among others, reflect the Company's current views about the Company's plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions the Company has m

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release dated January 13, 2025. 99.2 Slides from BridgeBio Pharma, Inc.'s J.P. Morgan Healthcare Conference Presentation, dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: January 13, 2025 By: /s/ Brian C. Stephenson Brian C. Stephenson Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.